mFOLFIRINOX + Ramucirumab
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreatic Cancer
Conditions
Pancreatic Cancer
Trial Timeline
Sep 11, 2016 → Jan 27, 2022
NCT ID
NCT02581215About mFOLFIRINOX + Ramucirumab
mFOLFIRINOX + Ramucirumab is a phase 2 stage product being developed by Eli Lilly for Pancreatic Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02581215. Target conditions include Pancreatic Cancer.
What happened to similar drugs?
9 of 20 similar drugs in Pancreatic Cancer were approved
Approved (9) Terminated (4) Active (11)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02581215 | Phase 2 | Completed |
Competing Products
20 competing products in Pancreatic Cancer